| Issue Type | XXXX |
|---|---|
| Country | Japan |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2050-09-09 |
| Par Value | 100000000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 60000.00 |
| Coupon | 1.55 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 60000.000 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Sumitomo Pharma Co. Ltd. corporate bond has a X.X % fixed-floating rate rate coupon paid on a XXXX basis. It was issued on MAR 12, 2000 with an issue size of XXX million JPY and matures on DEC 9, 2000 with a last coupon date of FEB 28, 2020. |
Sumitomo Pharma Co. Ltd. is a Japanese pharmaceutical company founded in 1897 and headquartered in Osaka, Japan, focusing on the research, development, and manufacturing of innovative pharmaceutical products. The company's portfolio includes a range of therapeutic areas such as psychiatry, neurology, and oncology, with notable products like the antipsychotic agent Latuda and the anti-cancer drug Sumitomo Dainippon Pharma's Epclusa.